🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#W, #WGS, #PEPG, #SPCE, #TBCH

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #W 4.5x
2. #PVH 4.2x
3. #WGS 3.6x
4. #PEPG 3.5x
5. #NKE 3.4x

#OptionFlow #OptionsTrading #Trading

PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data PepGen (Nasdaq: PEPG) reported topline Phase 2 FREEDOM2 5 mg/kg MAD cohort results (data cutoff March 4, 2026). PGN-EDODM1 was generally well tolerated with no serious adverse events and mainly mild TEAEs. Mean splicing correction was 7.3% (n=6) vs 6.8% placebo (n=2); excluding one outlier, treated mean was 22.9% (n=5).Middle finger vHOT trended positively versus placebo but returned to baseline by Week 16. Mean muscle concentration in five patients was 158 ng/g. Company expects 10 mg/kg cohort data in 2H 2026 and sufficient cash into 2H 2027.

#PEPG PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data

www.stocktitan.net/news/PEPG/pep-gen-announ...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#MOS, #LAW, #MLTX, #PEPG, #MT

#OptionFlow #OptionsTrading #Trading

PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights PepGen (Nasdaq: PEPG) reported 2025 year-end results and program updates highlighting clinical progress for PGN-EDODM1 in DM1 and a strong cash position. Key clinical readouts and regulatory actions are scheduled for 2026, and the company held $148.5M cash as of December 31, 2025.Notable details: FREEDOM Phase 1 showed dose-proportional tissue exposure and splicing correction up to 53.7% at 15 mg/kg; FREEDOM2 5 mg/kg data expected Q1 2026; 10 mg/kg cohort dosing proceeding with results due 2H 2026; USPTO issued a composition-of-matter patent extending U.S. exclusivity into H2 2042.

#PEPG PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/PEPG/pep-gen-report...

PepGen Announces Regulatory Updates on FREEDOM2 The U.S. Food and Drug Administration has placed a partial clinical hold on the FREEDOM2-DM1 Phase 2 multiple ascending dose, randomized, placebo-controlled clinical trial of PGN-EDODM1 in patients with myotonic dystrophy type 1. The partial clinical hold did not cite any questions regarding blinded clinical data from the Phase 1 FREEDOM study previously...

#PEPG PepGen Announces Regulatory Updates on FREEDOM2

www.stocktitan.net/news/PEPG/pep-gen-announ...

Leading Indicators, Monday January 5, 2026 – Crystal Equity Research

Small-cap stocks in new uptrend according to average directional index, Mon Jan 5th - #MYO #TIGR #SKYT #PEPG #NVCR #MRAM #GHRS #CSWC #AZ #WEAV #EVTL #CRI #ACVA - More: crystalequityresearch.com/leading-indi... - #smallcap

PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule PepGen (Nasdaq: PEPG) announced that the USPTO issued a composition-of-matter patent for its peptide-conjugated oligonucleotide candidate PGN-EDODM1 (Patent No. 12,465,646).The patent covers PGN-EDODM1 and PepGen’s proprietary Enhanced Delivery Oligonucleotide (EDO) platform chemistry, including its unique peptide and linker design, and is expected to provide U.S. exclusivity into the second half of 2042, with potential patent-term extension following FDA approval.Company leadership described the issuance as a milestone that complements PepGen’s expanding global patent estate and supports the program’s long-term clinical and commercial potential for treating myotonic dystrophy type 1.

#PEPG PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule

www.stocktitan.net/news/PEPG/pep-gen-announ...

#PEPG PepGen Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

www.stocktitan.net/news/PEPG/pep-gen-report...

Breaking News: ( NASDAQ: #PEPG ) PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #NTR 26.2x
2. #MOS 10.5x
3. #PEPG 10.4x
4. #AMPY 4.5x
5. #XPEV 4.5x

#OptionFlow #OptionsTrading #Trading

Most Searched, Thursday September 25, 2025 – Crystal Equity Research

Most searched small-cap stocks, Thu Sept 25th - #EOSE #BTBT #LAES #HTXZ #RR #BB #RXRX #HIVE #ONDS #BITF #EVAX #SPRC #DNN #PLUG #PEPG #SBET #QUBT #LAC #IMRX #AEO - More: crystalequityresearch.com/most-searche... - #smallcap

Just In: ( NASDAQ: #PEPG ) US Companies Moving the Markets, Evening edition <br>Thu, Sep 25, 2025 as of 4:00 pm ET

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #PEPG 6.3x
2. #AMPY 4.5x
3. #ESI 4.0x
4. #XPEV 3.3x
5. #KALV 3.1x

#OptionFlow #OptionsTrading #Trading

JUST IN: ( NASDAQ: #PEPG ) US Companies Moving the Markets, Morning edition <br>Thu, Sep 25, 2025 as of 10.00 am ET

📢 Stocks Trending NOW: #INTC #ACN #BB #QURE #FCX #PEPG #TSLA #ALAB #IBM #OPEN

Leading Indicators, Wednesday September 24, 2025 – Crystal Equity Research

Small-cap stocks with improving money flow, Wed Sept 24th - #WALD #VCIC #TNYA #SDST #QURE #PEPG #LINK #HOND #IAS #GNSS #COHU #APYX #OPAD #BKKT - More: crystalequityresearch.com/leading-indi... - #smallcap

Record-Breaking 53.7% Disease Correction: PepGen's DM1 Drug Achieves Unprecedented Clinical Results PepGen's PGN-EDODM1 achieves 53.7% splicing correction in DM1 patients at 15mg/kg dose, with 100% patient response. Drug well-tolerated with mild/moderate AEs. Phase 1 MAD study results due Q1 2026.

#PEPG PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients

www.stocktitan.net/news/PEPG/pep-gen-announ...

Had an amazing time at PEPG Workshop 2025 in Lisbon! It was great to gain hands-on experience in plant physiology techniques including chlorophyll fluorescence and gas exchange. Grateful to @sebiology.bsky.social and #PEPG for the opportunity to learn and connect with such a brilliant community!”

Kuehn Law Investigates Potential Misconduct by PepGen Inc. Executives Kuehn Law is urging PepGen Inc. investors to inquire about potential breaches by company officers and directors regarding fiduciary duties.

Kuehn Law Investigates Potential Misconduct by PepGen Inc. Executives #USA #New_York #Kuehn_Law #PepGen_Inc #PEPG

Faruqi & Faruqi Urges PepGen Investors to Act Before Lawsuit Deadline in 2025 PepGen investors are reminded of the upcoming deadline for a pending class action lawsuit, as Faruqi & Faruqi advocates legal action for those affected by the company's misstatements.

Faruqi & Faruqi Urges PepGen Investors to Act Before Lawsuit Deadline in 2025 #United_States #New_York #Faruqi_&_Faruqi #PEPG #PepGen

Leading Indicators, Thursday August 7, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Thu Aug 7th - #ULBI #TEAD #SANA #ROOT #PEPG #OCCI #MXCT #HNST #GENK #FWRG #ESTA #CLFD #BTMD #ATRO #UTI #TPVG #SMA #MLR #IIPR #BOW - More: crystalequityresearch.com/leading-indi... - #smallcap

Faruqi & Faruqi, LLP Leads Investigation into PepGen Inc. Securities Fraud Case Faruqi & Faruqi, a nationally recognized law firm, is examining claims related to PepGen Inc., urging affected investors to step forward and take action.

Faruqi & Faruqi, LLP Leads Investigation into PepGen Inc. Securities Fraud Case #United_States #New_York #Faruqi_&_Faruqi #PEPG #PepGen

PepGen Inc. Shareholders Urged to Join Class Action Against the Company for False Statements PepGen Inc. shareholders are encouraged to register for a class action lawsuit due to alleged misleading statements during the company's trial phases. Participation is free.

PepGen Inc. Shareholders Urged to Join Class Action Against the Company for False Statements #New_York #Class_Action #US #PepGen_Inc #PEPG

Faruqi & Faruqi Launches Investigation Into PepGen Amid Shareholder Concerns Faruqi & Faruqi, LLP is actively looking into claims from PepGen investors who suffered substantial losses from March 2024 to March 2025.

Faruqi & Faruqi Launches Investigation Into PepGen Amid Shareholder Concerns #United_States #New_York #Faruqi_&_Faruqi #PEPG #PepGen

Levi & Korsinsky Alerts PepGen Inc. Investors on Lawsuit Filing Deadline Levi & Korsinsky LLP notifies PepGen Inc. investors about a significant class action lawsuit with a deadline on August 8, 2025, seeking to recover losses.

Levi & Korsinsky Alerts PepGen Inc. Investors on Lawsuit Filing Deadline #United_States #New_York #Levi_&_Korsinsky #PepGen_Inc. #PEPG

Faruqi & Faruqi Urges PepGen Investors to Act Amid Class Action Lawsuit Deadline Faruqi & Faruqi, LLP advises PepGen investors about a forthcoming class action lawsuit with a crucial lead plaintiff deadline approaching on August 11, 2025.

Faruqi & Faruqi Urges PepGen Investors to Act Amid Class Action Lawsuit Deadline #United_States #New_York #Faruqi_&_Faruqi #PEPG #PepGen

PepGen Inc. Faces Class Action Lawsuit over Misleading Securities Information Claims Investors in PepGen Inc. have been urged to contact The Gross Law Firm regarding a class action lawsuit for alleged securities law violations before the deadline on August 8, 2025.

PepGen Inc. Faces Class Action Lawsuit over Misleading Securities Information Claims #United_States #New_York #The_Gross_Law_Firm #PepGen_Inc #PEPG

Legal Actions Intensify as PepGen Inc. Faces Securities Violation Claims Amid Investor Concerns PepGen Inc. is under scrutiny following a lawsuit alleging securities law violations, urging investors to connect with The Gross Law Firm for potential action.

Legal Actions Intensify as PepGen Inc. Faces Securities Violation Claims Amid Investor Concerns #United_States #New_York #Gross_Law_Firm #PepGen_Inc. #PEPG